1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Public Health
  4. Volume 45, 2024
  5. Article

Annual Review of Public Health

Volume 45, 2024

Warning Labels as a Public Health Intervention: Effects and Challenges for Tobacco, Cannabis, and Opioid Medications

Abstract

Warning labels help consumers understand product risks, enabling informed decisions. Since the 1966 introduction of cigarette warning labels in the United States, research has determined the most effective message content (health effects information) and format (brand-free packaging with pictures). However, new challenges have emerged. This article reviews the current state of tobacco warning labels in the United States, where legal battles have stalled pictorial cigarette warnings and new products such as electronic cigarettes and synthetic nicotine products pose unknown health risks. This article describes the emerging research on cannabis warnings; as more places legalize recreational cannabis, they are adopting lessons from tobacco warnings. However, its uncertain legal status and widespread underestimation of harms impede strict warning standards. The article also reviews opioid medication warning labels, suggesting that lessons from tobacco could help in the development of effective and culturally appropriate FDA-compliant opioid warning labels that promote safe medication use and increased co-dispensing of naloxone.

Keyword(s): cannabis, opioid medications, tobacco, warning labels
Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-060922-042254
2024-05-20
2024-05-23
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/45/1/annurev-publhealth-060922-042254.html?itemId=/content/journals/10.1146/annurev-publhealth-060922-042254&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Agarwal AK, Lee D, Ali Z, Wu Y, Cognilio M, et al. 2022.. Effect of mailing an at-home disposal kit on unused opioid disposal after surgery: a randomized clinical trial. . JAMA Netw. Open 5::e2210724
     [Crossref] [Google Scholar]
  2. 2.
    Al-Hamdani M, Joyce KM, Park T, Cowie ME, Stewart SH. 2021.. Cannabis packaging: an opportunity for facilitating informed decisions. . J. Consumer Aff. 55::1150–68
     [Crossref] [Google Scholar]
  3. 3.
    Allard NC, Kruger JS, Kruger DJ. 2023.. Cannabis advertising policies in the United States: state-level variation and comparison with Canada. . Cannabis Cannabinoid Res. 8::505–9
     [Crossref] [Google Scholar]
  4. 4.
    Bailey SC, Shrank WH, Parker RM, Davis TC, Wolf MS. 2009.. Medication label improvement: an issue at the intersection of health literacy and patient safety. . J. Commun. Healthc. 2::294–307
     [Crossref] [Google Scholar]
  5. 5.
    Barry RA, Glantz SA. 2017.. Lessons from tobacco for developing marijuana legalization policy. Rep. , Cent. Tob. Control Res. Educ., Univ. Calif., San Francisco:. http://www.escholarship.org/uc/item/87j477b7
  6. 6.
    Biecheler M-B, Peytavin J-F, SAM Group, Facy F, Martineau H. 2008.. SAM survey on “Drugs and Fatal Accidents”: search of substances consumed and comparison between drivers involved under the influence of alcohol or cannabis. . Traffic Inj. Prev. 9::11–21
     [Crossref] [Google Scholar]
  7. 7.
    Brewer NT, Hall MG, Noar SM, Parada H, Stein-Seroussi A, et al. 2016.. Effect of pictorial cigarette pack warnings on changes in smoking behavior: a randomized clinical trial. . JAMA Intern. Med. 176::905–12
     [Crossref] [Google Scholar]
  8. 8.
    Bridgeman MB, Abazia DT. 2017.. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. . Pharm. Ther. 42::180–88
     [Google Scholar]
  9. 9.
    Buckley NA, Rossi S. 2011.. Bringing greater transparency to “black box” warnings. . Clin. Toxicol. 49::448–51
     [Crossref] [Google Scholar]
  10. 10.
    Cameron L, Williams J. 2001.. Cannabis, alcohol and cigarettes: substitutes or complements?. Econ. Rec. 77::19–34
     [Crossref] [Google Scholar]
  11. 11.
    Cannabis Regul. Assoc. 2022.. CANNRA submits response to the discussion draft of the Cannabis Administration and Opportunity Act. Lett. Sept. 23 , CANNRA. https://www.cann-ra.org/news-events/cannra-issues-letter-to-congress-highlighting-regulatory-issues-which-impact-state-and-federal-priorities-2tk8l
  12. 12.
    CDC (Cent. Dis. Control Prev.). 2012.. Selected actions of the U.S. government regarding the regulation of tobacco sales, marketing, and use (excluding laws pertaining to agriculture or excise tax). . Regulation. http://www.cdc.gov/tobacco/data_statistics/by_topic/policy/legislation/
    [Google Scholar]
  13. 13.
    Chen Y, Wang Y, Nielsen S, Kuhn L, Lam T. 2020.. A systematic review of opioid overdose interventions delivered within emergency departments. . Drug Alcohol Depend. 213::108009
     [Crossref] [Google Scholar]
  14. 14.
    Chihuri S, Li G, Chen Q. 2017.. Interaction of marijuana and alcohol on fatal motor vehicle crash risk: a case-control study. . Inj. Epidemiol. 4::8
     [Crossref] [Google Scholar]
  15. 15.
    Cornelius ME, Loretan CG, Jamal A, Davis Lynn BC, Mayer M, et al. 2023.. Tobacco product use among adults—United States, 2021. . MMWR 72::475–83
     [Google Scholar]
  16. 16.
    Courtwright DT. 2009.. Dark Paradise: A History of Opiate Addiction in America. Cambridge, MA:: Harvard Univ. Press
  17. 17.
    Covvey JR. 2015.. Recent developments toward the safer use of opioids, with a focus on hydrocodone. . Res. Soc. Adm. Pharm. 11::901–8
     [Crossref] [Google Scholar]
  18. 18.
    Cox S, Frings D, Ahmed R, Dawkins L. 2018.. Messages matter: The Tobacco Products Directive nicotine addiction health warning versus an alternative relative risk message on smokers' willingness to use and purchase an electronic cigarette. . Addict. Behav. Rep. 8::136–39
     [Google Scholar]
  19. 19.
    Crosbie E, Thomson G. 2018.. Regulatory chills: tobacco industry legal threats and the politics of tobacco standardised packaging in New Zealand. . N. Z. Med. J. 131::25–41
     [Google Scholar]
  20. 20.
    Cunningham R. 2022.. Tobacco package health warnings: a global success story. . Tob. Control 31::272–83
     [Crossref] [Google Scholar]
  21. 21.
    Curfman G. 2021.. Graphic cigarette warning labels, the First Amendment, and public right to accurate public health information: graphic cigarette warning labels back under legal scrutiny. . JAMA Health Forum 2::e212886
     [Crossref] [Google Scholar]
  22. 22.
    Darke S, Farrell M. 2014.. Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment. . Addiction 109::1237–42
     [Crossref] [Google Scholar]
  23. 23.
    Darrow JJ, Avorn J, Kesselheim AS. 2020.. FDA approval and regulation of pharmaceuticals, 1983–2018. . JAMA 323::164–76
     [Crossref] [Google Scholar]
  24. 24.
    Davis TC, Federman AD, Bass PF 3rd, Jackson RH, Middlebrooks M, et al. 2009.. Improving patient understanding of prescription drug label instructions. . J. Gen. Intern. Med. 24::57–62
     [Crossref] [Google Scholar]
  25. 25.
    Discount Tobacco City & Lottery, Inc. v. United States Food & Drug Admin., 674 F.3d 509 (6th Cir . 2012.)
  26. 26.
    Donohue J. 2006.. A history of drug advertising: the evolving roles of consumers and consumer protection. . Milbank Q. 84::659–99
     [Crossref] [Google Scholar]
  27. 27.
    Erku DA, Bauld L, Dawkins L, Gartner CE, Steadman KJ, et al. 2021.. Does the content and source credibility of health and risk messages related to nicotine vaping products have an impact on harm perception and behavioural intentions? A systematic review. . Addiction 116::3290–303
     [Crossref] [Google Scholar]
  28. 28.
    FDA (Food Drug Adm.). 2018.. New safety measures announced for immediate release (IR) opioids. . Information by Drug Class. https://www.fda.gov/drugs/information-drug-class/new-safety-measures-announced-immediate-release-ir-opioids
    [Google Scholar]
  29. 29.
    FDA (Food Drug Adm.). 2020.. FDA requiring labeling changes for opioid pain medicines, opioid use disorder medicines regarding naloxone. News Release, July 23. https://www.fda.gov/news-events/press-announcements/fda-requiring-labeling-changes-opioid-pain-medicines-opioid-use-disorder-medicines-regarding
  30. 30.
    FDA (Food Drug Adm.). 2023.. New safety measures announced for extended-release and long-acting opioids. . Information by Drug Class. https://www.fda.gov/drugs/information-drug-class/new-safety-measures-announced-extended-release-and-long-acting-opioids
    [Google Scholar]
  31. 31.
    Garner M, Ning Z, Francis J. 2012.. A framework for the evaluation of patient information leaflets. . Health Expect. 15::283–94
     [Crossref] [Google Scholar]
  32. 32.
    Ghaddaf AA, Alsharef JF, Alhindi AK, Bahathiq DM, Khaldi SE, et al. 2022.. Influence of perioperative opioid-related patient education: a systematic review and meta-analysis. . Patient Educ. Couns. 105::2824–40
     [Crossref] [Google Scholar]
  33. 33.
    Goodman S, Hammond D. 2021.. Noticing of cannabis health warning labels in Canada and the US. . Health Promot. Chronic Dis. Prev. Can. 41::201–10
     [Crossref] [Google Scholar]
  34. 34.
    Goodman S, Leos-Toro C, Hammond D. 2022.. Do mandatory health warning labels on consumer products increase recall of the health risks of cannabis?. Subst. Use Misuse 57::569–80
     [Crossref] [Google Scholar]
  35. 35.
    Gov. Can. 2019.. Cannabis health warning messages. . Regulations under the Cannabis Act. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/regulations-support-cannabis-act/health-warning-messages.html
    [Google Scholar]
  36. 36.
    Gov. Can. 2022.. Cannabis regulations (SOR/2018–144). . Consolidated Regulations. https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-144/index.html
    [Google Scholar]
  37. 37.
    Griffin OH III, Spillane JF. 2013.. Pharmaceutical regulation failures and changes: lessons learned from OxyContin abuse and diversion. . J. Drug Issues 43::164–75
     [Crossref] [Google Scholar]
  38. 38.
    Hall W. 2018.. The future of the international drug control system and national drug prohibitions. . Addiction 113::1210–23
     [Crossref] [Google Scholar]
  39. 39.
    Hall W, Lynskey M. 2020.. Assessing the public health impacts of legalizing recreational cannabis use: the U.S. experience. . World Psychiatry 19::179–86
     [Crossref] [Google Scholar]
  40. 40.
    Hall W, Stjepanović D, Caulkins J, Lynskey M, Leung J, et al. 2019.. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. . Lancet 394::1580–90
     [Crossref] [Google Scholar]
  41. 41.
    Hall W, Weier M. 2015.. Assessing the public health impacts of legalizing recreational cannabis use in the USA. . Clin. Pharmacol. Ther. 97::607–15
     [Crossref] [Google Scholar]
  42. 42.
    Hammond D. 2011.. Health warning messages on tobacco products: a review. . Tob. Control 20::327–37
     [Crossref] [Google Scholar]
  43. 43.
    Hammond D. 2021.. Communicating THC levels and ‘dose’ to consumers: implications for product labelling and packaging of cannabis products in regulated markets. . Int. J. Drug Policy 91::102509
     [Crossref] [Google Scholar]
  44. 44.
    Hammond D, Goodman S, Wadsworth E, Rynard V, Boudreau C, Hall W. 2020.. Evaluating the impacts of cannabis legalization: the International Cannabis Policy Study. . Int. J. Drug Policy 77::102698
     [Crossref] [Google Scholar]
  45. 45.
    Hartman M. 2023.. Marijuana overview. Rep. , Natl. Conf. State Legis., Denver, CO:. https://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx
  46. 46.
    Hasin DS. 2018.. US epidemiology of cannabis use and associated problems. . Neuropsychopharmacology 43::195–212
     [Crossref] [Google Scholar]
  47. 47.
    Hassan LM, Shiu E. 2015.. No place to hide: two pilot studies assessing the effectiveness of adding a health warning to the cigarette stick. . Tob. Control. 24::e3–5
     [Crossref] [Google Scholar]
  48. 48.
    Heyward J, Olson L, Sharfstein JM, Stuart EA, Lurie P, Alexander GC. 2020.. Evaluation of the extended-release/long-acting opioid prescribing risk evaluation and mitigation strategy program by the US Food and Drug Administration: a review. . JAMA Intern. Med. 180::301–9
     [Crossref] [Google Scholar]
  49. 49.
    Hiilamo H, Crosbie E, Glantz SA. 2014.. The evolution of health warning labels on cigarette packs: the role of precedents, and tobacco industry strategies to block diffusion. . Tob. Control 23::e2
     [Crossref] [Google Scholar]
  50. 50.
    Hoek J, Gendall P, Eckert C, Louviere J. 2016.. Dissuasive cigarette sticks: the next step in standardised (‘plain’) packaging?. Tob. Control 25::699–705
     [Crossref] [Google Scholar]
  51. 51.
    Holitzki H, Dowsett LE, Spackman E, Noseworthy T, Clement F. 2017.. Health effects of exposure to second- and third-hand marijuana smoke: a systematic review. . CMAJ Open 5::E814–22
     [Crossref] [Google Scholar]
  52. 52.
    Hong SH, Liu J, Tak S, Vaidya V. 2013.. The impact of patient knowledge of patient-centered medication label content on quality of life among older adults. . Res. Soc. Adm. Pharm. 9::37–48
     [Crossref] [Google Scholar]
  53. 53.
    Humphreys K, Shover CL, Andrews CM, Bohnert AS, Brandeau ML, et al. 2022.. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford–Lancet Commission. . Lancet 399::555–604
     [Crossref] [Google Scholar]
  54. 54.
    Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE, Miech RA. 2014.. Monitoring the Future national survey results on drug use, 1975–2013: Volume I, Secondary school students. Rep. , Inst. Soc. Res., Univ. Mich., Ann Arbor, MI:. https://deepblue.lib.umich.edu/bitstream/handle/2027.42/137911/mtf-vol2_2014.pdf?sequence=1
  55. 55.
    Jones JM. 2019.. In U.S., medical aid top reason why legal marijuana favored. . Gallup, June 12. https://news.gallup.com/poll/258149/medical-aid-top-reason-why-legal-marijuana-favored.aspx
    [Google Scholar]
  56. 56.
    Kees J, Fitzgerald P, Dorsey JD, Hill RP. 2020.. Evidence-based cannabis policy: a framework to guide marketing and public policy research. . J. Public Policy Mark. 39::76–92
     [Crossref] [Google Scholar]
  57. 57.
    Kesselheim AS, Franklin JM, Avorn J, Duke JD. 2013.. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs. . BMJ Q. Saf. 22::727–34
     [Crossref] [Google Scholar]
  58. 58.
    Kim SJ, Minich M, Tveleneva A, Liu J, Padon AA, et al. 2022.. Textual and pictorial enhancement of cannabis warning labels: an online experiment among at-risk U.S. young adults. . Drug Alcohol Depend. 237::109520
     [Crossref] [Google Scholar]
  59. 59.
    Kimber C, Frings D, Cox S, Albery IP, Dawkins L. 2020.. Communicating the relative health risks of E-cigarettes: an online experimental study exploring the effects of a comparative health message versus the EU nicotine addiction warnings on smokers’ and non-smokers’ risk perceptions and behavioural intentions. . Addict. Behav. 101::106177
     [Crossref] [Google Scholar]
  60. 60.
    Kolb L, Du Mez AG. 1924.. The prevalence and trend of drug addiction in the United States and factors influencing it. . Public Health Rep. (1896–1970) 39:(21):1179–204
     [Crossref] [Google Scholar]
  61. 61.
    Kraemer JD, Baig SA. 2013.. Analysis of legal and scientific issues in court challenges to graphic tobacco warnings. . Am. J. Prev. Med. 45::334–42
     [Crossref] [Google Scholar]
  62. 62.
    Leos-Toro C, Fong GT, Meyer SB, Hammond D. 2019.. Perceptions of effectiveness and believability of pictorial and text-only health warning labels for cannabis products among Canadian youth. . Int. J. Drug Policy 73::24–31
     [Crossref] [Google Scholar]
  63. 63.
    Ling PM, Kim M, Egbe CO, Patanavanich R, Pinho M, Hendlin Y. 2022.. Moving targets: how the rapidly changing tobacco and nicotine landscape creates advertising and promotion policy challenges. . Tob. Control. 31::222–28
     [Crossref] [Google Scholar]
  64. 64.
    Lis Y, Roberts MH, Kamble S, Guo JJ, Raisch DW. 2012.. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group. . Value Health 15::1108–18
     [Crossref] [Google Scholar]
  65. 65.
    McCarthy DM, Curtis LM, Courtney DM, Cameron KA, Lank PM, et al. 2019.. A multifaceted intervention to improve patient knowledge and safe use of opioids: results of the ED EMC2 randomized controlled trial. . Acad. Emerg. Med. 26::1311–25
     [Crossref] [Google Scholar]
  66. 66.
    McCarthy DM, Wolf MS, McConnell R, Sears J, Chevrier A, et al. 2015.. Improving patient knowledge and safe use of opioids: a randomized controlled trial. . Acad. Emerg. Med. 22::331–39
     [Crossref] [Google Scholar]
  67. 67.
    McGinty EE, Niederdeppe J, Heley K, Barry CL. 2017.. Public perceptions of arguments supporting and opposing recreational marijuana legalization. . Prev. Med. 99::80–86
     [Crossref] [Google Scholar]
  68. 68.
    Meisel ZF, Shofer F, Dolan A, Goldberg EB, Rhodes KV, et al. 2022.. A multicentered randomized controlled trial comparing the effectiveness of pain treatment communication tools in emergency department patients with back or kidney stone pain. . Am. J. Public Health 112::S45–55
     [Crossref] [Google Scholar]
  69. 69.
    Mercadante S, Craig D, Giarratano A. 2012.. US Food and Drug Administration's risk evaluation and mitigation strategy for extended-release and long-acting opioids: pros and cons, and a European perspective. . Drugs 72::2327–32
     [Crossref] [Google Scholar]
  70. 70.
    Moodie C, Hoek J, Hammond D, Gallopel-Morvan K, Sendoya D, et al. 2022.. Plain tobacco packaging: progress, challenges, learning and opportunities. . Tob. Control 31::263–71
     [Crossref] [Google Scholar]
  71. 71.
    Mullen RJ, Duhig J, Russell A, Scarazzini L, Lievano F, Wolf MS. 2018.. Best-practices for the design and development of prescription medication information: a systematic review. . Patient Educ. Couns. 101::1351–67
     [Crossref] [Google Scholar]
  72. 72.
    Mutti-Packer S, Collyer B, Hodgins DC. 2018.. Perceptions of plain packaging and health warning labels for cannabis among young adults: findings from an experimental study. . BMC Public Health 18::1361
     [Crossref] [Google Scholar]
  73. 73.
    Natl. Inst. Drug Abuse. 2023.. Drug overdose death rates. . Trends & Statistics. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates#:∼:text=Drug%20overdose%20deaths%20involving%20prescription,involving%20prescription%20opioids%20totaled%2016%2C706
    [Google Scholar]
  74. 74.
    Newman CL, Mason MJ, Langenderfer J. 2021.. The shifting landscape of cannabis legalization: potential benefits and regulatory perspectives. . J. Consum. Aff. 55::1169–77
     [Crossref] [Google Scholar]
  75. 75.
    Newsweek. 1959.. Cigarettes: one man's meat…. . Newsweek, Feb. 4. https://industrydocuments.library.ucsf.edu/tobacco/docs/#id=yrgm0137
    [Google Scholar]
  76. 76.
    Noar SM, Barker J, Bell T, Yzer M. 2020.. Does perceived message effectiveness predict the actual effectiveness of tobacco education messages? A systematic review and meta-analysis. . Health Commun. 35::148–57
     [Crossref] [Google Scholar]
  77. 77.
    Noar SM, Francis DB, Bridges C, Sontag J, Ribisl KM, Brewer NT. 2016.. The impact of strengthening cigarette pack warnings: systematic review of longitudinal observational studies. . Soc. Sci. Med. 164::118–29
     [Crossref] [Google Scholar]
  78. 78.
    Noar SM, Hall MG, Francis DB, Ribisl KM, Pepper JK, Brewer NT. 2016.. Pictorial cigarette pack warnings: a meta-analysis of experimental studies. . Tob. Control 25::341–54
     [Crossref] [Google Scholar]
  79. 79.
    Orenstein DG, Glantz SA. 2018.. Regulating cannabis manufacturing: applying public health best practices from tobacco control. . J. Psychoact. Drugs 50::19–32
     [Crossref] [Google Scholar]
  80. 80.
    Orenstein DG, Glantz SA. 2020.. Cannabis legalization in state legislatures: public health opportunity and risk. . Marquette Law Rev. 103::1313–400
     [Google Scholar]
  81. 81.
    Owusu D, Lawley R, Yang B, Henderson K, Bethea B, et al. 2020.. ‘ The lesser devil you don't know’: a qualitative study of smokers’ responses to messages communicating comparative risk of electronic and combusted cigarettes. . Tob. Control 29::217–23
     [Google Scholar]
  82. 82.
    Pepper JK, Lee YO, Eggers ME, Allen JA, Thompson J, Nonnemaker JM. 2020.. Perceptions of U.S. and Canadian cannabis package warnings among U.S. adults. . Drug Alcohol Depend. 217::108275
     [Crossref] [Google Scholar]
  83. 83.
    Pons EdS, Moraes CG, Falavigna M, Sirtori LR, da Cruz F, et al. 2019.. Users’ preferences and perceptions of the comprehensibility and readability of medication labels. . PLOS ONE 14::e0212173
     [Crossref] [Google Scholar]
  84. 84.
    Public Health Law Cent. 2023.. R.J. Reynolds v. FDA 2020. Litigation Tracker. https://www.publichealthlawcenter.org/litigation-tracker/rj-reynolds-tobacco-company-et-al-v-us-food-and-drug-administration-et-al-2020
    [Google Scholar]
  85. 85.
    Redford A, Powell B. 2016.. Dynamics of intervention in the War on Drugs: the buildup to the Harrison Act of 1914. . Indep. Rev. 20::509–30
     [Google Scholar]
  86. 86.
    R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205 (D.C. Cir . 2012.)
  87. 87.
    Rogers WA, Lamson N, Rousseau GK. 2000.. Warning research: an integrative perspective. . Hum. Factors 42::102–39
     [Crossref] [Google Scholar]
  88. 88.
    Rollman JE, Heyward J, Olson L, Lurie P, Sharfstein J, Alexander GC. 2019.. Assessment of the FDA risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products. . JAMA 321::676–85
     [Crossref] [Google Scholar]
  89. 89.
    Salloum NC, Krauss MJ, Agrawal A, Bierut LJ, Grucza RA. 2018.. A reciprocal effects analysis of cannabis use and perceptions of risk. . Addiction 113::1077–85
     [Crossref] [Google Scholar]
  90. 90.
    Sanders MS, McCormick EJ. 1993.. Human Factors in Engineering and Design. New York:: McGraw-Hill. , 7th ed..
  91. 91.
    Schauer GL. 2021.. Cannabis policy in the United States: implications for public health. . J. Natl. Cancer Inst. Monogr. 58::39–52
     [Crossref] [Google Scholar]
  92. 92.
    Schrot RJ, Hubbard JR. 2016.. Cannabinoids: medical implications. . Ann. Med. 48::128–41
     [Crossref] [Google Scholar]
  93. 93.
    Shi Y, Cao Y, Shang C, Pacula RL. 2019.. The impacts of potency, warning messages, and price on preferences for Cannabis flower products. . Int. J. Drug Policy 74::1–10
     [Crossref] [Google Scholar]
  94. 94.
    Shimazawa R, Ikeda M. 2013.. Safety information in drug labeling: a comparison of the USA, the UK, and Japan. . Pharmacoepidemiol. Drug Saf. 22::306–18
     [Crossref] [Google Scholar]
  95. 95.
    Shrank W, Avorn J, Rolon C, Shekelle P. 2007.. Medication safety: effect of content and format of prescription drug labels on readability, understanding, and medication use: a systematic review. . Ann. Pharmacother. 41::783–801
     [Crossref] [Google Scholar]
  96. 96.
    Shrank WH, Avorn J. 2007.. Educating patients about their medications: the potential and limitations of written drug information. . Health Aff. 26::731–40
     [Crossref] [Google Scholar]
  97. 97.
    Spillane JF. 2004.. Debating the Controlled Substances Act. . Drug Alcohol Depend. 76::17–29
     [Crossref] [Google Scholar]
  98. 98.
    Stephenson J. 2022.. FDA gains power to regulate synthetic nicotine in e-cigarettes. . JAMA Health Forum 3::e221140
     [Crossref] [Google Scholar]
  99. 99.
    Swann JP. 1994.. FDA and the practice of pharmacy: prescription drug regulation before the Durham-Humphrey Amendment of 1951. . Pharm. Hist. 36::55–70
     [Google Scholar]
  100. 100.
    Tam J, Jeon J, Thrasher JF, Hammond D, Holford TR, et al. 2021.. Estimated prevalence of smoking and smoking-attributable mortality associated with graphic health warnings on cigarette packages in the US from 2022 to 2100. . JAMA Health Forum 2::e212852
     [Crossref] [Google Scholar]
  101. 101.
    Tob. Control Leg. Consort. 2015.. Cigarette graphic warnings and the divided federal courts. FDA Tob. Proj. , Tob. Control Leg. Consort., Saint Paul, MN:. https://publichealthlawcenter.org/sites/default/files/resources/Tobacco-Control-Legal-Consortium-Cigarette-Graphic-Warnings-and-the-Divided-Federal-Courts.pdf
  102. 102.
    Tob. Inst. 1959.. We have just been informed that the UPI wire carried a story on the introduction… Lett. From EF Ragland, Jan. 8. https://industrydocuments.library.ucsf.edu/tobacco/docs/#id=hhgc0086
  103. 103.
    Truth Tob. Ind. Doc. 1959.. Part VI - Summary of state labeling legislation. Doc. gymh0045 , Truth Tob. Ind. Doc., UCSF, San Francisco:. https://industrydocuments.library.ucsf.edu/tobacco/docs/#id=gymh0045
  104. 104.
    US Dep. Health Hum. Serv. 1994.. Preventing Tobacco Use Among Young People: A Report of the Surgeon General. Atlanta:: US Dep. Health Hum. Serv.
  105. 105.
    US Drug Enforc. Adm. 2022.. The Controlled Substances Act. . Drug Information. https://www.dea.gov/drug-information/csa
    [Google Scholar]
  106. 106.
    Van Zee A. 2009.. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. . Am. J. Public Health 99::221–27
     [Crossref] [Google Scholar]
  107. 107.
    Wackowski OA, Rashid M, Greene KL, Lewis MJ, O'Connor RJ. 2020.. Smokers’ and young adult non-smokers’ perceptions and perceived impact of snus and e-cigarette modified risk messages. . Int. J. Environ. Res. Public Health 17::6807
     [Crossref] [Google Scholar]
  108. 108.
    Wang X, Derakhshandeh R, Liu J, Narayan S, Nabavizadeh P, et al. 2016.. One minute of marijuana secondhand smoke exposure substantially impairs vascular endothelial function. . J. Am. Heart Assoc. 5::e003858
     [Crossref] [Google Scholar]
  109. 109.
    WHO (World Health Organ.). 2003.. WHO Framework Convention on Tobacco Control. Geneva:: WHO. https://iris.who.int/bitstream/handle/10665/42811/9241591013.pdf
  110. 110.
    Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. 2016.. Marijuana legalization: impact on physicians and public health. . Annu. Rev. Med. 67::453–66
     [Crossref] [Google Scholar]
  111. 111.
    Wilson KM, Torok MR, Wei B, Wang L, Robinson M, et al. 2017.. Detecting biomarkers of secondhand marijuana smoke in young children. . Pediatr. Res. 81::589–92
     [Crossref] [Google Scholar]
  112. 112.
    Winstock AR, Lynskey MT, Maier LJ, Ferris JA, Davies EL. 2021.. Perceptions of cannabis health information labels among people who use cannabis in the U.S. and Canada. . Int. J. Drug Policy 91::102789
     [Crossref] [Google Scholar]
  113. 113.
    Wolf MS, Davis TC, Curtis LM, Bailey SC, Knox JP, et al. 2016.. A patient-centered prescription drug label to promote appropriate medication use and adherence. . J. Gen. Intern. Med. 31::1482–89
     [Crossref] [Google Scholar]
  114. 114.
    Wolf MS, King J, Wilson EAH, Curtis LM, Bailey SC, et al. 2012.. Usability of FDA-approved medication guides. . J. Gen. Intern. Med. 27::1714–20
     [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-publhealth-060922-042254
Loading
Warning Labels as a Public Health Intervention: Effects and Challenges for Tobacco, Cannabis, and Opioid Medications
Annual Review of Public Health 45, 425 (2024); https://doi.org/10.1146/annurev-publhealth-060922-042254
/content/journals/10.1146/annurev-publhealth-060922-042254
/content/journals/10.1146/annurev-publhealth-060922-042254
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error